Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Alx Oncology Holdings Inc (NQ: ALXO ) 1.450 +0.020 (+1.40%) Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Alx Oncology Holdings Inc < Previous 1 2 3 4 5 Next > ALX Oncology Announces Initial Data from ASPEN-05 Study of Evorpacept in Combination with Azacitidine and Venetoclax, Demonstrating Tolerability and Preliminary Activity in Patients with Acute Myeloid Leukemia December 12, 2022 From ALX Oncology Via GlobeNewswire ALX Oncology Appoints Scott Garland to its Board of Directors November 29, 2022 From ALX Oncology Via GlobeNewswire ALX Oncology Reports Third Quarter 2022 Financial Results and Provides Clinical Development and Operational Highlights November 08, 2022 From ALX Oncology Via GlobeNewswire ALX Oncology's Evorpacept Gets Orphan Drug Tag For Gastric Cancer January 28, 2022 The Via Benzinga ALX Oncology to Present New Clinical Data on Evorpacept in Acute Myeloid Leukemia at 64th ASH Annual Meeting November 03, 2022 From ALX Oncology Via GlobeNewswire ALX Oncology Announces Upcoming Investor Conference Participation November 02, 2022 From ALX Oncology Via GlobeNewswire ALX Oncology Enters $100 Million Loan Facility Agreement with Oxford Finance and Silicon Valley Bank to Support Ongoing Development of Evorpacept October 31, 2022 Expects to extend cash runway to mid-2025 From ALX Oncology Via GlobeNewswire ALX Oncology Announces Trials in Progress Abstracts Accepted for Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting October 05, 2022 From ALX Oncology Via GlobeNewswire Recap Of Thursday's Biotech Catalysts - End Of the Day Summary August 11, 2022 Via Benzinga ALX Oncology Shares Climb As Mid-Stage Triple Combination Colorectal Cancer Study Kicks-off August 11, 2022 ALX Oncology Holdings (NASDAQ: ALXO) has initiated a Phase 2 investigator-sponsored study of evorpacept in combination with Eli Lilly’s (NYSE: LLY) ERBITUX (cetuximab) and Merck’s (NASDAQ: Via Benzinga Recap Of Monday's Biotech Catalysts - End Of the Day Summary August 01, 2022 Via Benzinga Daily Biotech Pulse: Celyad Resumes Colorectal Cancer Trial, Setback For Otonomy, AstraZeneca Halts Phase 3 Head, Neck Cancer Trial August 01, 2022 Here's a roundup of top developments in the biotech space over the last 24 hours: Via Benzinga ALX Oncology Shares Gain As FDA Grants Fast Track Status To Head And Neck Cancer Candidate August 01, 2022 ALX Oncology Holdings (NASDAQ: ALXO) receives Fast Track designation from the U.S. Food and Drug Administration (FDA) for its lead asset Evorpacept in combination with KEYTRUDA (pembrolizumab) for the... Via Benzinga 12 Health Care Stocks Moving In Tuesday's After-Market Session July 12, 2022 Gainers Guardant Health (NASDAQ:GH) stock rose 14.8% to $55.23 during Tuesday's after-market session. The market value of their outstanding shares is at $5.6 billion. Via Benzinga The Daily Biotech Pulse: Eli Lilly Modifies COVID-19 Treatment Pact, Oyster Point Outlines Restructuring Plan, Icosavax Posts Interim RSV Vaccine Data June 29, 2022 Here's a roundup of top developments in the biotech space over the last 24 hours: Via Benzinga ALX Oncology Shares Soar As FDA Grants Orphan Drug Status To Blood Cancer Candidate June 29, 2022 The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to ALX Oncology Holdings’ (NASDAQ: ALXO) Evorpacept for the treatment of patients with acute myeloid leukemia (AML). Via Benzinga 12 Health Care Stocks Moving In Wednesday's Pre-Market Session June 29, 2022 Via Benzinga Stocks That Hit 52-Week Lows On Monday June 06, 2022 Monday's session saw 84 companies set new 52-week lows. Via Benzinga Stocks That Hit 52-Week Lows On Tuesday May 31, 2022 On Tuesday, 36 companies achieved new lows for the year. Via Benzinga ALX Oncology Holdings: Q4 Earnings Insights February 28, 2022 ALX Oncology Holdings (NASDAQ:ALXO) reported its Q4 earnings results on Monday, February 28, 2022 at 07:00 AM. Here's what investors need to know about the announcement... Via Benzinga The Daily Biotech Pulse: Biogen Liquidates Out Of Biosimilar JV, Provention Bio Plots Diabetes Drug Resubmission, Merck Finds COVID Pill Effective Against Omicron January 28, 2022 Here's a roundup of top developments in the biotech space over the last 24 hours: Via Benzinga Stocks That Hit 52-Week Lows On Wednesday January 26, 2022 During Wednesday's morning session, 34 stocks hit new 52-week lows. Things to Consider About Today's 52-Week Lows: Illumina (NASDAQ:ILMN) was the biggest company... Via Benzinga 12 Health Care Stocks Moving In Wednesday's Pre-Market Session January 26, 2022 Gainers Vaccinex (NASDAQ:VCNX) shares moved upwards by 30.4% to $1.33 during Wednesday's pre-market session. The market value of their outstanding shares is at $40.9... Via Benzinga Gastrointestinal Cancer Treatment Trials Driven by Rising Incidences of Colorectal Cancer January 20, 2022 Palm Beach, FL – January 20, 2022 – FinancialNewsMedia.com News Commentary – Despite significant progress in the treatment of gastric cancer, it is still among the leading causes of deaths due to... Via FinancialNewsMedia Topics Death Exposures Death Benzinga's Top Ratings Upgrades, Downgrades For December 22, 2021 December 22, 2021 Upgrades According to Loop Capital, the prior rating for Williams-Sonoma Inc (NYSE: Via Benzinga 10 Biggest Price Target Changes For Wednesday December 22, 2021 Barclays lifted the price target on FactSet Research Systems Inc. (NYSE: Via Benzinga ALX Oncology's Evorpacept Data Fails To Impress At ASH Presentation December 13, 2021 ALX Oncology Holdings Inc (NASDAQ: ALXO) presented initial clinical data from its ongoing Phase 1 / 2 trial evaluating evorpacept combined with azacitidine for... Via Benzinga 58 Biggest Movers From Yesterday December 14, 2021 Gainers Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) shares jumped 80.4% to close at $90.08 on Monday. Pfizer agreed to acquire Arena Pharmaceuticals for $100 per share in an all-... Via Benzinga 40 Stocks Moving In Monday's Mid-Day Session December 13, 2021 Gainers Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) shares climbed 83.4% to $91.52. Pfizer agreed to acquire Arena Pharmaceuticals for $100 per share in an all-cash transaction.... Via Benzinga 75 Biggest Movers From Yesterday November 10, 2021 Find out what's going on in today's market and bring any questions you have to Benzinga's PreMarket Prep. Check out these big penny stock gainers and losers... Via Benzinga < Previous 1 2 3 4 5 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
